OTC : GIFLF

Grifols, S.A.

$10.45 USD

$0.2 (1.95%)

Volume
5.78K
Average Volume
367
Market Capitalization
$7.11B
P/E Ratio
15.44
Dividend Yield
0.87%
Price Target
Year High
$14.00
Year Low
$10.13
Day High
—
Day Low
—
Payout Ratio
$0.31
Current Ratio
$2.47
Company Overview

OTC

Jose Ignacio Abia Buenache

Drug Manufacturers - General

Healthcare

GIFLF

23833

ES

USD

https://www.grifols.com

34 93 571 02 21

N/A

0001438569

Liquidity Metrics

1.77

2.47

0.85

0.33

0.31

Sales & Valuation

$7.52B

0.86

1.17

8.50

1.11

Profitability

$0.59

$401.74M

5.58%

8.23%

7.88%

2.07%

P/E Metrics

15.44

0.13

0.13

Analyst Price Target & Rating

Neutral

3/5

7 Analysts

%

Company Executives
Name Title
Ignacio Ramal Subira Chief Internal Audit & Enterprise Risk Manager
Vicente Blanquer Torre Chief Quality Officer
Montse Ribas Chief Communications and Reputation Officer
Daniel Segarra Head of Investor Relations & Sustainability and Vice President
Camille Alpi Chief Human Resources & Talent Officer
Daniel Fleta Coit Chief Industrial Services Officer
David Ian Bell Chief Corporate Affairs & Legal Officer
Enrique de la Torre Chief Compliance Officer
Jose Ignacio Abia Buenache Chief Executive Officer & Director
Lluis Pons Gomez Senior Vice President of Strategy & Chief Operating Officer Office
Rahul Srinivasan Chief Financial Officer
Sergio Roura Adell President of Commercial Tech Support
Poll Results

No votes yet today — be the first to share your view!

About Grifols, S.A. (OTC:GIFLF) Stock

Grifols, S.A., a company established in Barcelona, Spain, in 1940, specializes in the sourcing, production, and sale of therapeutic products, principally derived from blood plasma. Its diverse activities are structured across five main divisions. The Bioscience division spearheads the research, development, manufacturing, and commercialization of plasma-derived medications and novel solutions designed to treat chronic, rare, widespread, and life-threatening diseases. Its portfolio includes immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. Through its Hospital division, Grifols supplies non-biological pharmaceutical products and medical provisions, encompassing clinical nutrition, intravenous therapies, and various medical devices. The Diagnostic di ... vision focuses on developing and distributing diagnostic tools that support healthcare professionals throughout the patient journey, from prevention and screening to accurate diagnosis, prognosis, and continuous treatment monitoring. Additionally, the Bio Supplies division furnishes crucial biological materials for scientific research, clinical trials, and the production of pharmaceutical and diagnostic goods. Grifols' products and services are employed by healthcare providers to both diagnose and manage a range of conditions, such as hemophilia, immune deficiencies, and infectious diseases. The company caters to a broad spectrum of public and private customers, including wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care facilities, and national health systems. Grifols also engages in a technology collaboration agreement with Mondragon.

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

2026-07-03 10:49:07

First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

2026-06-15 08:00:00

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

2026-05-09 15:31:13

Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Grifols, S.A. (GIFLF) stock price?

Grifols, S.A.(OTC:GIFLF) stock price is $10.45 in the last trading session. During the trading session, GIFLF stock reached the peak price of $14 while $10.13 was the lowest point it dropped to. The percentage change in GIFLF stock occurred in the recent session was 1.95% while the dollar amount for the price change in GIFLF stock was $0.2.

GIFLF's industry and sector of operation?

The OTC listed GIFLF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of GIFLF?

Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager
Vicente Blanquer Torre | Chief Quality Officer
Montse Ribas | Chief Communications and Reputation Officer
Daniel Segarra | Head of Investor Relations & Sustainability and Vice President
Camille Alpi | Chief Human Resources & Talent Officer

How many employees does GIFLF have?

Number of GIFLF employees currently stands at 23833. GIFLF operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.

Link for GIFLF official website?

Official Website of GIFLF is: https://www.grifols.com

How do I contact GIFLF?

GIFLF could be contacted at phone #34 93 571 02 21 and can also be accessed through its website. GIFLF operates from Avinguda de la Generalitat, 152, Barcelona, CT 08174, ES.

How many shares of GIFLF are traded daily?

The average number of GIFLF shares traded daily for last 3 months was 367.

What is the market cap of GIFLF currently?

The market value of GIFLF currently stands at $7.11B with its latest stock price at $10.45